Combined MEK and Pi3′-kinase inhibition reveals synergy in targeting thyroid cancer <i>in vitro</i> and <i>in vivo</i>Oussama ElMokh, Roch‐Philippe Charles|Oncotarget|2017Cited by 25
Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agentAnne-Julie Cloux, Aimable Nahimana, Oussama ElMokh et al.|Oncotarget|2019Cited by 22
Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemiaOussama ElMokh, Michel A. Duchosal, Saki Matsumoto et al.|Cell Death and Disease|2022Cited by 16